TY - JOUR
T1 - A joint international consensus statement for measuring quality of survival for patients with childhood cancer
AU - van Kalsbeek, Rebecca J
AU - Hudson, Melissa M
AU - Mulder, Renée L
AU - Ehrhardt, Matthew
AU - Green, Daniel M
AU - Mulrooney, Daniel A
AU - Hakkert, Jessica
AU - den Hartogh, Jaap
AU - Nijenhuis, Anouk
AU - van Santen, Hanneke M
AU - Schouten-van Meeteren, Antoinette Y N
AU - van Tinteren, Harm
AU - Verbruggen, Lisanne C
AU - Conklin, Heather M
AU - Jacola, Lisa M
AU - Webster, Rachel Tillery
AU - Partanen, Marita
AU - Kollen, Wouter J W
AU - Grootenhuis, Martha A
AU - Pieters, Rob
AU - Kremer, Leontien C M
N1 - Funding Information:
We thank the survivors that participated in the focus groups to share their experiences with life after childhood cancer. We also thank W. Plieger for her valuable contribution to the preparation, conduct and interpretation of the focus groups.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2023/6
Y1 - 2023/6
N2 - The aim of treating childhood cancer remains to cure all. As survival rates improve, long-term health outcomes increasingly define quality of care. The International Childhood Cancer Outcome Project developed a set of core outcomes for most types of childhood cancers involving relevant international stakeholders (survivors; pediatric oncologists; other medical, nursing or paramedical care providers; and psychosocial or neurocognitive care providers) to allow outcome-based evaluation of childhood cancer care. A survey among healthcare providers (n = 87) and online focus groups of survivors (n = 22) resulted in unique candidate outcome lists for 17 types of childhood cancer (five hematological malignancies, four central nervous system tumors and eight solid tumors). In a two-round Delphi survey, 435 healthcare providers from 68 institutions internationally (response rates for round 1, 70-97%; round 2, 65-92%) contributed to the selection of four to eight physical core outcomes (for example, heart failure, subfertility and subsequent neoplasms) and three aspects of quality of life (physical, psychosocial and neurocognitive) per pediatric cancer subtype. Measurement instruments for the core outcomes consist of medical record abstraction, questionnaires and linkage with existing registries. This International Childhood Cancer Core Outcome Set represents outcomes of value to patients, survivors and healthcare providers and can be used to measure institutional progress and benchmark against peers.
AB - The aim of treating childhood cancer remains to cure all. As survival rates improve, long-term health outcomes increasingly define quality of care. The International Childhood Cancer Outcome Project developed a set of core outcomes for most types of childhood cancers involving relevant international stakeholders (survivors; pediatric oncologists; other medical, nursing or paramedical care providers; and psychosocial or neurocognitive care providers) to allow outcome-based evaluation of childhood cancer care. A survey among healthcare providers (n = 87) and online focus groups of survivors (n = 22) resulted in unique candidate outcome lists for 17 types of childhood cancer (five hematological malignancies, four central nervous system tumors and eight solid tumors). In a two-round Delphi survey, 435 healthcare providers from 68 institutions internationally (response rates for round 1, 70-97%; round 2, 65-92%) contributed to the selection of four to eight physical core outcomes (for example, heart failure, subfertility and subsequent neoplasms) and three aspects of quality of life (physical, psychosocial and neurocognitive) per pediatric cancer subtype. Measurement instruments for the core outcomes consist of medical record abstraction, questionnaires and linkage with existing registries. This International Childhood Cancer Core Outcome Set represents outcomes of value to patients, survivors and healthcare providers and can be used to measure institutional progress and benchmark against peers.
UR - https://www.scopus.com/pages/publications/85161840447
U2 - 10.1038/s41591-023-02339-y
DO - 10.1038/s41591-023-02339-y
M3 - Article
C2 - 37322119
SN - 1078-8956
VL - 29
SP - 1340
EP - 1348
JO - Nature Medicine
JF - Nature Medicine
IS - 6
ER -